

# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/768,872	01/23/2001	Rina Aharoni	60772-PCT-US/JPW/GJG/CSN 3801	
7	7590 08/27/2002		_	
John P. White			EXAMINER	
Cooper & Dunham LLP 1185 Avenue of the Americas New York, NY 10036			DECLOUX, AMY M	
			ART UNIT	PAPER NUMBER
			1644	N/s
			DATE MAILED: 08/27/2002	14

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n N .	Applicant(s)			
	09/768,872	AHARONI ET AL.			
Office Action Summary	Examiner	Art Unit			
!	Amy M. DeCloux	1644			
Th MAILING DATE of this c mmunication app Peri df r Reply	ears n the cov r sheet with the c	rresp ndence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply 1 If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status	2222				
1) Responsive to communication(s) filed on <u>06 J</u>					
,	s action is non-final.				
3) Since this application is in condition for allowal closed in accordance with the practice under I Disposition of Claims					
4)⊠ Claim(s) <u>1-46</u> is/are pending in the application					
4a) Of the above claim(s) <u>5-15,21-31 and 40-46</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) <u>1-4,16-20 and 32-39</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.				
Application Papers					
9) The specification is objected to by the Examine					
10) The drawing(s) filed on & b is/are: a) accept	oted or b)□ objected to by the Exa	miner.			
Applicant may not request that any objection to the					
11) The proposed drawing correction filed on		ved by the Examiner.			
If approved, corrected drawings are required in rep					
12)☐ The oath or declaration is objected to by the Ex	aminer.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>					
2. Certified copies of the priority documents have been received in Application No					
<ul> <li>Copies of the certified copies of the prior application from the International But</li> <li>* See the attached detailed Office action for a list</li> </ul>	reau (PCT Rule 17.2(a)).	. <del>.</del>			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language pro	visional application has been rec	eived.			
Attachment(s)	5 phoney under 00 0.0.0, 33 120	CHICK OF TAIL			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 13	5) Notice of Informal I	r (PTO-413) Paper No(s) Patent Application (PTO-152)			

Art Unit: 1644

#### **DETAILED ACTION**

The substitute specification filed 1-23-01 has not been entered because it does not conform to 37 CFR 1.125(b) because: there is no accompanying statement that there is no new matter.

A substitute specification filed under 37 CFR 1.125(a) must only contain subject matter from the original specification and any previously entered amendment under 37 CFR 1.121. If the substitute specification contains additional subject matter not of record, the substitute specification must be filed under 37 CFR 1.125(b) and must be accompanied by: 1) a statement that the substitute specification contains no new matter; and 2) a marked-up copy showing the amendments to be made via the substitute specification relative to the specification at the time the substitute specification is filed.

It is noted that a marked up copy of the specification was attached to the substitute specification filed 1-23-01.

Claims 1-46 are pending.

### Election/Restrictions

Applicant's election with traverse of Group I, claims 1-4, 16-20 and 32-39, and the species multiple sclerosis, in Paper No. 11, is acknowledged. The traversal is on the ground(s) that all of the inventions I-VIII consist essentially of three of the four amino acids in copolymer I. This is not found persuasive because each invention has a distinct structure and biophysical properties as outlined in the restriction requirement mailed 3-26-02, and the presence of shared amino acids does not overcome this distinctness. Applicants further assert that it would not be an undue burden for the examiner to examine and search Inventions I-IV and V-VIII and IX. This is not found persuasive because though the searches are overlapping, they are not coextensive, and thus searching and examining Inventions I-IV and V-VIII and IX would require an undue burden on the examiner. It is noted that at present Invention I has not been found to be allowable, therefore Invention V will not be joined with Invention V presently.

The requirement is still deemed proper and is therefore made FINAL.

Claims 5-15, 21-31 and 40-46 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 11, filed 6-6-02.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

.

Application/Control Number: 09/768,872 Page 3

Art Unit: 1644

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 16-20 and 32-39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 16-20 and 32-39 are indefinite in their recitation of non-elected subject material. Specifically independent claim 16 encompasses polymers in addition to the terpolymer of the elected invention encompassing a terpolymer consisting essentially of tyrosine, alanine and lysine randomly polymerized into a polypeptide.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(f) he did not himself invent the subject matter sought to be patented.

Claims 1-4 are rejected under 35 U.S.C. 102(f) because the applicant did not invent the claimed subject matter. The instant specification discloses on page 31 of the substitute specification and page 34 of the originally filed specification that the terpolymer consisting essentially of tyrosine, alanine and lysine randomly polymerized into a polypeptide, wherein said tyrosine is present in a mole fraction of about 0.102, said alanine is present in a mole fraction of about 0.542, and said lysine is present in a mole fraction of about 0.353 was obtained from Teva Pharmaceuticals Industry. It is noted that Teva Pharmaceuticals Industry is not an assignee either. Clarification is required in order to overcome this rejection.

#### Conclusion

No Claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy M. DeCloux whose telephone number is 703 306-5821. The examiner can normally be reached on M-F 8:00-5:30.

Application/Control Number: 09/768,872

Art Unit: 1644

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703 308-3973. The fax phone numbers for the organization where this application or proceeding is assigned are 703 305-3014 for regular communications and 703 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0196.

Amy DeCloux, Ph.D., Patent Examiner, August 23, 2002 Patrick J. Nolan,

**Primary Patent Examiner** 

Page 4